含奥利司他的减肥计划对肥胖女性血清瘦素水平的影响：一项为期12周的随机安慰剂对照研究。
Effects of a weight-reduction program with orlistat on serum leptin levels in obese women: A 12-week, randomized, placebo-controlled study.
作者信息
Ozcelik Oguz, Dogan Halil, Kelestimur Haluk
机构信息
Departments of Physiology Faculty of Medicine, University of Firat, Elazig, Turkey.
Endocrinology and Metabofic Disease, Faculty of Medicine, University of Firat, Elazig, Turkey.
出版信息
Curr Ther Res Clin Exp. 2004 Mar;65(2):127-37. doi: 10.1016/S0011-393X(04)90025-2.
BACKGROUND
Leptin, which has been identified as an antiobesity hormone, regulates body weight by controlling food intake and energy expenditure via the hypothalamic-pituitary-gonadal axis. It appears that leptin may be an important factor in obesity management. Orlistat, a pancreatic lipase inhibitor, could reduce fat absorption and promote weight loss due to leptin metabolism.
OBJECTIVE
The purpose of this study was to investigate the effects of orlistat therapy on serum leptin levels.
METHODS
Obese women (body mass index [BMI], 30 kg/m(2)) aged 18 to 50 years were randomly assigned to receive 12 weeks of oral treatment with diet-orlistat (120 mg TID) (DO group) or diet-placebo (DP group). During the treatment period, patients were asked to eat a balanced diet of -1200 to 1600 kcal/d. Body composition was determined by bioelectrical impedance. Serum leptin levels were measured using radioimmunoassay at baseline and at study end.
RESULTS
A total of 24 patients entered the study; 14 patients (mean [SE] BMI, 37.7 [1.1] kg/m(2)) received orlistat and 10 patients (mean [SE] BMI, 39.4 [1.3] kg/m(2)) received placebo. Compared with baseline, mean percentages of loss of body weight and fat mass after 12 weeks of treatment were significant in the DO group (9.1% and 14.8%, respectively; both P = 0.001) and in the DP group (9.5% and 17.6%; both P = 0.005). The between-group differences were not statistically significant. Mean (SE) serum leptin levels also decreased significantly after treatment in the DO group (16.2 [1.2] vs 9.0 [1.0] ng/mL; P = 0.001) and in the DP group (19.3 [2.1] vs 9.7 [1.4] ng/mL; P = 0.005). The between-group difference was not statistically significant.
CONCLUSIONS
In this study of obese women, orlistat treatment was associated with a similar decrease in body weight, fat mass, and serum leptin levels as placebo over a 12-week period. In this regard, short-term orlistat therapy may not provide an additional effect on serum leptin levels, and reduction in leptin levels were closely related to the decrease in fat mass.
背景
瘦素已被确定为一种抗肥胖激素，它通过下丘脑 - 垂体 - 性腺轴控制食物摄入和能量消耗来调节体重。瘦素似乎可能是肥胖管理中的一个重要因素。奥利司他是一种胰脂肪酶抑制剂，由于其对瘦素代谢的作用，可减少脂肪吸收并促进体重减轻。
目的
本研究旨在探讨奥利司他治疗对血清瘦素水平的影响。
方法
将年龄在18至50岁的肥胖女性（体重指数[BMI]，30kg/m²）随机分为两组，分别接受为期12周的饮食 - 奥利司他（120mg，每日三次）口服治疗（DO组）或饮食 - 安慰剂治疗（DP组）。在治疗期间，要求患者食用能量为1200至1600千卡/天的均衡饮食。通过生物电阻抗法测定身体成分。在基线和研究结束时使用放射免疫分析法测量血清瘦素水平。
结果
共有24名患者进入研究；14名患者（平均[标准误]BMI，37.7[1.1]kg/m²）接受奥利司他治疗，10名患者（平均[标准误]BMI，39.4[1.3]kg/m²）接受安慰剂治疗。与基线相比，DO组治疗12周后体重和脂肪量的平均减少百分比显著（分别为9.1%和14.8%；P均 = 0.001），DP组也显著（9.5%和17.6%；P均 = 0.005）。组间差异无统计学意义。DO组治疗后平均（标准误）血清瘦素水平也显著降低（16.2[1.2]对9.0[1.0]ng/mL；P = 0.001），DP组同样显著（19.3[2.1]对9.7[1.4]ng/mL；P = 0.005）。组间差异无统计学意义。
结论
在这项针对肥胖女性的研究中，在12周的时间里，奥利司他治疗与安慰剂相比，体重、脂肪量和血清瘦素水平的降低相似。在这方面，短期奥利司他治疗可能不会对血清瘦素水平产生额外影响，瘦素水平的降低与脂肪量的减少密切相关。
Zotero 插件